William Harrison - Merck Lead Independent Director

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:3em;padding-top: 38px;;'>MRK</div>
MRK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

Mr. William B. Harrison Jr. is no longer Lead Independent Director of Merck Co Inc. He is Retired Chairman of the Board JPMorgan Chase Co. since 2007 prior to which he was Chairman beginning in 2000 and Chief Executive Officer from 1999 until 2006. Chairman Cadence Bancorp LLC since 2010 Director Aurora Capital Group since 2007 Lincoln Center for the Performing Arts since 2006 RecoverCare LLC since 2009 and ThHarrisone University of North Carolina Endowment Fund Member Board of Overseers of Memorial SloanKettering Cancer Center and the National September 11 Memorial Museum Foundation. Mr. Harrison was also a director of Merck Sharp Dohme Corporationration from 1999 to 2009 and Cousins Properties Incorporated from 2006 to 2012.
Age: 70  Director Since 2009      
908 735-1500  www.merck.com

William Harrison Latest Insider Activity

Merck Management Efficiency

Merck Inc has Return on Asset of 0.0013 % which means that on every $100 spent on asset it made $0.0013 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.0039 % implying that it generated $0.0039 on every 100 dollars invested. Merck management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to increase to 24.06, while Return on Average Assets are estimated to decrease to 0.0013. Merck Goodwill and Intangible Assets are decreasing as compared to previous years. The last year's value of Goodwill and Intangible Assets was reported at 33.62 Billion. The current Total Assets Per Share is estimated to increase to 37.39, while Asset Turnover is estimated to decrease to 0.55. Merck Total Liabilities is increasing as compared to previous years. The last year's value of Total Liabilities was reported at 58.4 Billion. The current Liabilities Non Current is estimated to increase to about 39 B, while Current Liabilities is estimated to decrease to under 19.2 B.
The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck Inc has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Jamere JacksonEli Lilly And
Laurie GlimcherGlaxoSmithKline PLC
William KaelinEli Lilly And
Anne MulcahyJohnson Johnson
Luis BobadillaGrifols S A
Dimitri AzarNovartis AG
Hans WijersGlaxoSmithKline PLC
Thomas LynchGW Pharmaceuticals Plc
Simon DingemansGlaxoSmithKline PLC
Kelly KramerGilead Sciences
Ton BuechnerNovartis AG
Srikant DatarNovartis AG
Elizabeth DohertyNovartis AG
Carina LazaroGrifols S A
Togo WestBristol Myers Squibb
Stephanie BurnsGlaxoSmithKline PLC
William WaldegraveGW Pharmaceuticals Plc
Anna LluchGrifols S A
Etienne DavignonGilead Sciences
Steven MayerGrifols S A
Ann FudgeNovartis AG

Company Summary

It operates through Pharmaceutical and Animal Health segments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 71000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States and employs 71,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Inc Leadership Team

Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Rochelle Lazarus, Independent Director
Christine Seidman, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Franklin Clyburn, Executive Vice President Chief Commercial Officer
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Clark Golestani, CIO and Executive VP
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now


Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page